What is erytroblastosis fetalis?

erytroblastosis fetalis, also known as a hemolytic disease of the newborn, is a serious blood disorder that can occur when the fetus and mother have incompatible types of blood. This condition may be fatal for infants and can also lead to serious complications such as organ damage to the developing fetus. It is possible to take a number of steps to avoid erytroblastosis fetalis and to resolve the situation when they appear, another reason why mothers should receive routine prenatal care. In both cases, the mother develops antibodies against the baby's blood and these antibodies enter the fetus, destroy red blood cells and cause anemia and many other complications. The condition is most common during the second pregnancy after the mother has been exposed to an incompatible blood type by supplying a healthy child or through the potrates when fetal blood can enter the mother's body. Erytroblastosis fetalis can also be induced by blood transfusion with incompatible blood.

In the first trimester of pregnancy, women have a blood test that can determine whether or not erytroblastosis fetalis are endangered. For example, if the mother is negative, the father may be tested to see if RH is positive, suggesting that erytroblastosis fetalis can develop. Mother's blood can also be tested for antibodies for incompatible blood types. If erythroblastosis fetalis occurs, pregnancy will be carefully monitored. Treatment may include blood transfusions for the fetus or timely birth as soon as the fetus is viable to prevent damage to erytroblastosis fetalis.

women may reduce the risk of incompatibility of RH by accepting Rhogam up to 72 hours of anario. This immunoglobulin kills fetal cells in the mother's blood before having a chance to develop antibodies on them, which means that her future pregnancy should not be complicated by the incompatibility of RH. Injections are also recommended after the abortion of RH positive PLOdu for the same reason.

The incompatibility of

RH was significantly reduced by the use of immunoglobulin injections, which reduced the number of cases of erytroblastosis fetalis. Women who intend to have children in the future after pregnancy or abortion should discuss RH incompatibility with their doctor to determine whether they need injections.